{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:07:09Z","timestamp":1782169629786,"version":"3.54.5"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Catheter ablation has become a well-established indication for long-term rhythm control in atrial fibrillation (AF) patients refractory to anti-arrhythmic drugs (AADs). Efficacy and safety of AF catheter ablation (AFCA) before AADs failure are, instead, questioned.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> The aim of the study was to perform a systematic review and meta-analysis of randomized clinical trials (RCTs) comparing first-line AFCA with AADs in symptomatic patients with paroxysmal AF.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We performed a random-effects meta-analysis of binary outcome events comparing AFCA with AADs in rhythm control-na\u00efve patients. The primary outcomes, also stratified by the type of ablation energy (radiofrequency or cryoenergy), were (1) recurrence of atrial tachyarrhythmias and (2) recurrence of symptomatic atrial tachyarrhythmias. The secondary outcomes included adverse events.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Six RCTs were included in the analysis. AFCA was associated with lower recurrences of atrial tachyarrhythmias [relative risk (RR) 0.58, 95% confidence interval (CI) 0.46\u20130.72], consistent across the two types of ablation energy (radiofrequency, RR 0.50, 95% CI 0.28\u20130.89; cryoenergy, RR 0.60, 95% CI 0.50\u20130.72; <jats:italic>p<\/jats:italic>-value for subgroup differences: 0.55). Similarly, AFCA was related to less symptomatic arrhythmic recurrences (RR 0.46, 95% CI 0.27\u20130.79). Overall, adverse events did not differ. A trend toward increased periprocedural cardiac tamponade or phrenic nerve palsy was observed in the AFCA group, while more atrial flutter episodes with 1:1 atrioventricular conduction and syncopal events were reported in the AAD group.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> First-line rhythm control therapy with AFCA, independent from the adopted energy source (radiofrequency or cryoenergy), reduces long-term arrhythmic recurrences in patients with symptomatic paroxysmal AF compared with AADs.<\/jats:p>","DOI":"10.3389\/fcvm.2021.664647","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T04:46:57Z","timestamp":1621572417000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Catheter Ablation vs. Anti-Arrhythmic Drugs as First-Line Treatment in Symptomatic Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials"],"prefix":"10.3389","volume":"8","author":[{"given":"Andrea","family":"Saglietto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorenzo","family":"Gaita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"De Ponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano Maria","family":"De Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Anselmino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"CD005049","DOI":"10.1002\/14651858.CD005049.pub5","article-title":"Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation","volume":"2019","author":"Valembois","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1161\/CIRCEP.108.824789","article-title":"Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses","volume":"2","author":"Calkins","year":"2009","journal-title":"Circ Arrhythmia Electrophysiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1161\/CIRCEP.119.008128","article-title":"Diagnosis-to-Ablation time and recurrence of atrial fibrillation following catheter ablation: a systematic review and meta-analysis of observational studies.","volume":"13","author":"Chew","year":"2020","journal-title":"Circ Arrhythmia Electrophysiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1161\/CIRCEP.114.001853","article-title":"Catheter ablation and antiarrhythmic drug therapy as first- or second-line therapy in the management of atrial fibrillation: systematic review and meta-analysis","volume":"7","author":"Khan","year":"2014","journal-title":"Circ Arrhythmia Electrophysiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2019.0693","article-title":"Effect of catheter ablation vs. antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: The CABANA randomized clinical trial","volume":"321","author":"Packer","year":"2019","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: A report of the American college of Cardiology\/American heart association task force on practice guidelines and the heart rhythm society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.hrthm.2013.05.013","article-title":"Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes","volume":"10","author":"Bunch","year":"2013","journal-title":"Hear Rhythm."},{"key":"B9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijcard.2019.03.036","article-title":"Early choice for catheter ablation reduced readmission in management of atrial fibrillation: impact of diagnosis-to-ablation time","volume":"291","author":"Kawaji","year":"2019","journal-title":"Int J Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1001\/jama.293.21.2634","article-title":"Radiofrequency ablation vs. antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial","volume":"293","author":"Wazni","year":"2005","journal-title":"J Am Med Assoc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1056\/NEJMoa1113566","article-title":"Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation","volume":"367","author":"Cosedis Nielsen","year":"2012","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/jama.2014.467","article-title":"Radiofrequency ablation vs. antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2) a randomized trial","volume":"311","author":"Morillo","year":"2014","journal-title":"JAMA."},{"key":"B13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/europace\/euu376","article-title":"Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis","volume":"17","author":"Hakalahti","year":"2015","journal-title":"Europace."},{"key":"B14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2029980","article-title":"Cryoablation or drug therapy for initial treatment of atrial fibrillation","volume":"384","author":"Andrade","year":"2020","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2029554","article-title":"Cryoballoon ablation as initial therapy for atrial fibrillation","volume":"384","author":"Wazni","year":"2020","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euab029","article-title":"Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation","author":"Kuniss","year":"2021","journal-title":"EP Eur"},{"key":"B17","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ."},{"key":"B18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"B19","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/heartjnl-2016-309781","article-title":"Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomised clinical trial","volume":"103","author":"Nielsen","year":"2017","journal-title":"Heart."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1111\/jce.14584","article-title":"Inpatient hospital procedural volume and outcomes following catheter ablation of atrial fibrillation","volume":"31","author":"Cheung","year":"2020","journal-title":"J Cardiovasc Electrophysiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/jce.13484","article-title":"Temporal trends in safety and complication rates of catheter ablation for atrial fibrillation","volume":"29","author":"Muthalaly","year":"2018","journal-title":"J Cardiovasc Electrophysiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/europace\/eux373","article-title":"Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and International Society of Cardiovascular Pharmacotherapy (ISCP)","volume":"20","author":"Dan","year":"2018","journal-title":"Europace."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/jce.14429","article-title":"Impact of atrial fibrillation catheter ablation on mortality, stroke, and heart failure hospitalizations: a meta-analysis","volume":"31","author":"Saglietto","year":"2020","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1093\/eurheartj\/ehw285","article-title":"Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: Reintervention, rehospitalization, and quality-of-life outcomes in the FIRE and ICE trial","volume":"37","author":"Kuck","year":"2016","journal-title":"Eur Heart J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/eurheartj\/ehw564","article-title":"Contemporarymanagement of patients undergoing atrial fibrillation ablation: inhospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry","volume":"38","author":"Arbelo","year":"2017","journal-title":"Eur Heart J."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.664647\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T04:46:59Z","timestamp":1621572419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.664647\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":25,"alternative-id":["10.3389\/fcvm.2021.664647"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.664647","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"article-number":"664647"}}